MonoFerric Patient Solutions™

MONOFERRIC PATIENT SOLUTIONS™ PROGRAM

Rapid Response, Customized Solutions

Services offered through the Monoferric Patient Solutions Program include insurance coverage and reimbursement information, patient assistance program, copay assistance, nursing support, and more

Sample Monoferric® (ferric derisomaltose) Patient That May Qualify for Patient Services

Diagnosed with Iron Deficiency Anemia (IDA):

Patient who has intolerance to oral iron or have had unsatisfactory response to oral iron

AND / OR

Patient who has non-hemodialysis chronic kidney disease (NDD-CKD)

To learn more, call **800-992-9022** or visit **monoferric-patient-solutions.com**

INDICATION

Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:

- who have intolerance to oral iron or have had unsatisfactory response to oral iron
- who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.

Please see additional Important Safety Information throughout.
Please see full Prescribing Information here.

PHARMACOSMOS THERAPEUTICS

MonoFerric® (ferric derisomaltose) injection

About Monoferric

- Monoferric is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients
- Monoferric provides a single, rapid infusion and can be administered in no less than 20 minutes



How does it work?

- Monoferric has an innovative matrix structure which enables high iron concentrations with a controlled, slow release

Dosing

- For patients weighing 50 kg or more: Administer 1,000 mg of Monoferric as an intravenous infusion
- For patients weighing less than 50 kg: Administer Monoferric as 20 mg/kg actual body weight as an intravenous infusion
- Repeat Monoferric treatment if iron deficiency anemia reoccurs
- Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

Please see additional Important Safety Information throughout.
Please see full Prescribing Information here.

Monoferric Patient Solutions™

Monoferric Patient Solutions is committed to providing a seamless access journey to patients and healthcare providers

Live Representatives are available to support patients, caregivers, and healthcare providers through the various Monoferric Patient Solutions:

- Benefits verification
- Claims and appeals assistance
- Sample letters of appeal and/or medical necessity
- Prior authorization assistance
- Financial assistance
- In person support for provider's offices by providing access to a local field reimbursement manager

Supplemental Nursing Program

- Provides live peer-to-peer nursing support
- Patient care support prior to infusion:
  - Provide alternate infusion site information
  - Referral to advocacy resources

To learn more about this support program, or to enroll your patient, please call **800-992-9022**

IMPORTANT SAFETY INFORMATION (continued)

Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components. In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.

Please see additional Important Safety Information throughout.
Please see full Prescribing Information here.

How to enroll in any of the available support services (Reimbursement, Patient Assistance Program, Copay, Nursing):

Enrollment form can be found on-line:

- Your healthcare provider may enroll you online via the portal **monoferricpatientsolutionsportal.com**
- You or your healthcare provider may also download the editable form from **monoferric-patient-solutions.com**, complete the required fields, and fax to **833-888-8837**

Monoferric Patient Solutions may contact you and/or your healthcare provider for additional information in order to initiate next steps.

Monoferric Patient Solutions™ Patient Assistance Program

Manageable Requirements to Facilitate Access

Eligibility Criteria:

- Fall within the income guidelines*
- Uninsured or under-insured
- Must be 18 years or older
- Prescribed Monoferric for an on-label diagnosis
- Patient must be a resident of the United States (residency includes anyone who lives in one of the US states, the District of Columbia, Puerto Rico, and U.S. Virgin Islands). Citizenship or legal status is not a requirement.

To learn more, call **800-992-9022**
or visit **monoferric-patient-solutions.com**

*Pharmacosmos Therapeutics Inc. and its authorized third-party agents will use the patient's date of birth or social security number and/or additional demographic information as needed to access credit information and information derived from public and other sources to estimate income in conjunction with the eligibility determination process. As a soft credit inquiry, this option will not impact credit scores. Pharmacosmos Therapeutics Inc. and its authorized third-party agents reserve the right to ask for additional documents and information at any time.

IMPORTANT SAFETY INFORMATION (continued)

Iron Overload

Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferric to patients with iron overload.

Please see additional Important Safety Information throughout.
Please see full Prescribing Information here.

Monoferric Patient Solutions™ Copay Program

Patients pay as little as $0 per dose*

Eligibility Information:

To be eligible to participate in the Copay Program, you must:

- Have commercial health insurance† (i.e. health insurance offered through an employer; NOT Medicare, Medicare Advantage, Medicaid, TRICARE, or Veteran Affairs health care)
- Reside in the United States or Puerto Rico
- Be treated by a healthcare professional in the United States or Puerto Rico
- Be 18 years of age or older
- Be prescribed Monoferric for an on-label diagnosis

If you're eligible to participate:

- You will receive savings on out-of-pocket expenses‡ (i.e. deductible, copay or coinsurance obligations) for Monoferric of up to $1000 per dose
- If IDA returns, a second dose may be covered and you would receive an annual maximum savings on out-of-pocket expenses of up to $2000 (on a total of 2 doses)¶

To find out if you are eligible to enroll in the Monoferric Patient Solutions Program, call **800-992-9022** or advise your healthcare provider to visit the on-line portal at **monoferricpatientsolutionsportal.com**

* Maximum benefit of up to $1,000 per dose.

† Cash paying patients may also qualify.

‡ Only includes costs associated with Monoferric and does not apply to cost of administration.

¶ If patient's IDA returns in the same calendar year Pharmacosmos Therapeutics Inc. will cover another product dose. Additional restrictions apply. Please see full Terms and Conditions on **monoferric-patient-solutions.com**.

IMPORTANT SAFETY INFORMATION (continued)

ADVERSE REACTIONS

Adverse reactions were reported in 8.6% (172/2008) of patients treated with Monoferric. Adverse reactions related to treatment and reported by ≥1% of the treated patients were nausea (1.2%) and rash (1%). Adjudicated serious or severe hypersensitivity reactions were reported in 6/2008 (0.3%) patients in the Monoferric group. Hypophosphatemia (serum phosphate <2.0 mg/dL) was reported in 3.5% of Monoferric-treated patients in Trials 1 & 2.

Please see additional Important Safety Information throughout.
Please see full Prescribing Information here.

MONOFERRIC PATIENT SOLUTIONS™ DELIVERS DIVERSE SUPPORT TO ADDRESS IDA TREATMENT NEEDS

Rapid Response, Customized Solutions



Supplemental Nursing Program
Live peer-to-peer nursing support
Patient care support

Reimbursement Support
Billing and coding guide
Sample annotated claim forms
Sample letters of appeal and medical necessity

Copay Support
Available for patients with commercial health insurance*

Coverage and Access Information
Live representatives available
Benefits verification support
Prior authorization support
Buy and bill information
Claims and appeals assistance
HCP/patient portal

On-Demand Field Reimbursement Support
to assist with your patients reimbursement needs
Patient benefits verification
case follow-up

Patient Assistance Program available for patients who are underinsured or uninsured

* Cash paying patients may also qualify

To report adverse events, please contact Pharmacosmos at [1-888-828-0655]. You may also contact the FDA at **www.fda.gov/medwatch** or call 1-800-FDA-1088.

Please see full Prescribing Information here.

MonoFerric Patient Solutions™

Pharmacosmos Therapeutics Inc.
776 Mountain Blvd, Suite 101B
Watchung, NJ 07069

PHARMACOSMOS THERAPEUTICS

MonoFerric® (ferric derisomaltose) injection